Home » Stocks » CCCC

C4 Therapeutics, Inc. (CCCC)

Stock Price: $40.37 USD 0.79 (2.00%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 1.71B
Revenue (ttm) 30.06M
Net Income (ttm) -52.11M
Shares Out 40.67M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $40.37
Previous Close $39.58
Change ($) 0.79
Change (%) 2.00%
Day's Open 39.74
Day's Range 38.63 - 41.01
Day's Volume 168,240
52-Week Range 22.80 - 41.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

– Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 – – Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 –

GlobeNewsWire - 2 weeks ago

WATERTOWN, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively ...

InvestorPlace - 2 weeks ago

An FDA nod on Isoray's prostate treatment using brachytherapy seeds sent ISR stock skyrocketing. There's risk with uncertain reward in this biopharma stock.

GlobeNewsWire - 2 weeks ago

– Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 T...

Seeking Alpha - 4 weeks ago

C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders. Blockbuster drugs like Revlimid and Pomalyst are now known to be protei...

GlobeNewsWire - 1 month ago

WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively dest...

About CCCC

C4 Therapeutics, a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E a... [Read more...]

Industry
Biological Product (except Diagnostic) Manufacturing
IPO Date
Oct 2, 2020
Stock Exchange
NASDAQ
Ticker Symbol
CCCC
Full Company Profile

Financial Performance

In 2019, CCCC's revenue was $21.38 million, an increase of 10.42% compared to the previous year's $19.36 million. Losses were -$34.10 million, 117.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CCCC stock is "Strong Buy." The 12-month stock price forecast is 42.67, which is an increase of 5.70% from the latest price.

Price Target
$42.67
(5.70% upside)
Analyst Consensus: Strong Buy